Viktor Grünwald
0000-0003-2083-7687
Publication & Citation Trends
Publications
637 total
B2B: Bladder Cancer Summary
Cited by 0
Semantic Scholar
B2B: Kidney Cancer Summary
Cited by 0
Semantic Scholar
Histotype-specific incidence and survival of urothelial carcinoma—an analysis of the German North Rhine-Westphalia Cancer Registry
Cited by 0
Semantic Scholar
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Cited by 2
Semantic Scholar
MyCODE: A prospective evaluation of Lay-language Molecular Tumor Board Protocols in Precision Oncology
Cited by 0
Semantic Scholar
Autophagy suppression via SRC induction represents a therapeutic vulnerability for BAP1-mutant cancers
Cited by 6
Semantic Scholar
First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex
Cited by 0
Semantic Scholar
OPTILATER: optimal long-term survival after cancer – a cross-sectional study protocol for a quantitative survey on the care situation of long-term cancer survivors in Germany
Cited by 0
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(330)
Renal and related cancers
(163)
Cancer Immunotherapy and Biomarkers
(131)
Cancer Genomics and Diagnostics
(130)
Bladder and Urothelial Cancer Treatments
(90)
Affiliations
Goethe University Frankfurt
Novartis (Switzerland)
Memorial Sloan Kettering Cancer Center
University of Bonn
Hochschule Hannover